Ozempic Market - Therapeutic Indication (Type 2 Diabetes Mellitus (T2DM)), By Dosage (0.25 mg, 0.5 mg, 1 mg), By Treatment Duration (Short-term Therapy (for acute glycemic control), Long-term Maintenance Therapy), By Patient Demographics (Adult Population (age 18-64), Elderly Population (age 65+)), By Route of Administration (Subcutaneous Injection), By Combination Therapy (Monotherapy, Combination Therapy with Oral Antidiabetic Drugs (OADs), Combination Therapy with Insulin), By Adverse Effects Profile (Gastrointestinal Side Effects (nausea, vomiting, diarrhea), Hypoglycemia, Injection-site Reactions, Weight Loss), By End-user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies), By Prescription Status (Prescription Only), By Healthcare Setting (Urban healthcare settings, Rural healthcare settings), By Comorbidity (Patients with Cardiovascular Disease (CVD), Patients with Renal Impairment, Patients with Hepatic Impairment), By Cost (High-cost, Mid-cost, Low-cost). By Patient Compliance (Adherent patients, Non-adherent patients), By Special Population (Pregnant Women with T2DM, Pediatric Population with T2DM (limited use in this population)), By Physician Specialty (Endocrinologists, Primary Care Physicians (PCPs), Diabetologists), and By Country (Germany, United Kingdom, France, Spain, Italy, Russia, Rest of Europe)

$2400.00